Dare Bioscience (NASDAQ:DARE) Issues Quarterly Earnings Results

Dare Bioscience (NASDAQ:DARE – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05), Zacks reports. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%.

Here are the key takeaways from Dare Bioscience’s conference call:

  • DARE to PLAY dispensing is planned to begin in November after product shipment to Medvantx. The company reported prescriptions from 182 office-based providers and across 48 states and Washington, D.C., though initial dispensing will be limited to 28 states.
  • Flora Sync LF5 has early signs of traction, with orders from 27 states, a first provider-office reorder, and a 4.9-star rating from approximately 25 reviews. Revenue so far was not material; Daré plans to add Amazon distribution in early 2027 and is developing two related products.
  • Daré expects data in 2027 from its Ovaprene phase III and DARE-HPV phase II programs. Grant funding continues to support development, including recent installments for DARE-LARC1 and the Ovaprene trial, while the company explores potential partnerships around its drug-delivery platform.
  • Commercial revenue remains very small and liquidity is limited: third-quarter revenue was about $48,000, cash was $11.5 million, and working capital was $3.2 million. The company reported a $3.2 million quarterly net loss, although that was lower than the prior-year loss.

Dare Bioscience Stock Performance

DARE traded down $0.07 during trading on Monday, hitting $0.58. The stock had a trading volume of 196,841 shares, compared to its average volume of 374,724. The company has a market capitalization of $11.49 million, a PE ratio of -0.83 and a beta of 1.11. Dare Bioscience has a twelve month low of $0.58 and a twelve month high of $3.78. The stock has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $1.51.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Benchmark restated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. Ladenburg Thalmann & Co. Inc. began coverage on Dare Bioscience in a report on Monday, October 26th. They issued a “buy” rating and a $2.00 price target on the stock. Finally, UBS Group set a $1.00 price target on Dare Bioscience in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dare Bioscience has a consensus rating of “Moderate Buy” and an average target price of $5.00.

View Our Latest Research Report on Dare Bioscience

About Dare Bioscience

(Get Free Report)

Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.

Read More

Earnings History for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.